IRCT20180602039941N1 IRCT 2020-09-29 Arak University of Medical Sciences The effect of Neurobion in the treatment of Thalassemia The effectiveness of Neurobion in improving the general health of patients with thalassemia major referred to the hospital 2018-12-22 anticipated 40 Complete https://irct.ir/trial/50844 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Supportive, Randomization description: Children with betaThalassemia major over 10 years of age willing to cooperate and sign informed written consent to participate in the study having at least two years of transfusion history at least 20 days after the last transfusion at the time of blood transfusion specific treatment with Deferoxamine ) Neurobion supplementation with Deferoxamine, Blinding description: The researcher, participants, physician, and statistical analyst were blinded in this study, meaning that none of the neurons consumed by the patients were known. 0 (exploratory trials) Major Thalassemia. Intervention 1: Intervention group: Twenty Patients with Thalassemia major over 10 years of age who receive Neurobion. Intervention 2: Control group:Patients with Thalassemia major over the age of 10 receive a placebo. No - There is not a plan to make this available Justification or reason for not sharing IPD is Lack of access to complete personal information